Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

87.34 +0.52 (+0.60%)
Streaming Delayed Price Updated: 9:38 AM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
62 63 Next >
New Study Suggests Omicron Booster Isn't Needed — And Moderna Dips
A test found Moderna's booster and an omicron booster performed similarly in monkeys. 
Via Investor's Business Daily
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed. 
Via Benzinga
Germany's Vaccine Commission Recommends Novavax's COVID-19 Vaccine For Adults: Reuters
Germany's expert panel on vaccine use has recommended Novavax Inc's (NASDAQ: 
Via Benzinga
7 Hot Stocks That Can Win in Either a Bull or Bear Market
In today’s hyper-sensitive market, investors are searching for those defensive hot stocks that can weather all storms. 
Via InvestorPlace
Avoid Novavax for Now, Until the Picture Clears Up
NVAX stock may have seen a near-term bounce following the completion of filing of EUA filing with the FDA, but it may not be a buy yet. 
Via InvestorPlace
Could This Be A Potential New Weapon In The Fight Against COVID-19?
Photo by Mufid Majnun on Unsplash 
Via Benzinga
FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children
Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) have  
Via Benzinga
A Peek Into The Markets: US Stock Futures Edge Lower Following Monday's Surge; Alphabet Earnings in Focus
Pre-open movers 
Via Benzinga
Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S. 
Via Benzinga
Novavax: The Fall of a Covid-19 Vaccine Star
Novavax is finally starting to deliver effective Covid-19 vaccines in quantity around the world, but investors have moved on from NVAX stock. 
Via InvestorPlace
Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot?
Currently, analysts expect Moderna sales to drop off after 2022. 
Via Investor's Business Daily
A Look Into Healthcare Sector Value Stocks
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
After Pfizer, Moderna Kickstarts Omicron-Targeted COVID-19 Vaccine Trial
Moderna Inc (NASDAQ: MRNA) has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically  
Via Benzinga
Uncertain Market Conditions And Good News Make Novavax A Cautious Buy
An emergency use authorization in Australia is the latest example of the “yeah but” narrative that has plagued NVAX stock for the past year. 
Via InvestorPlace
What Are Whales Doing With BioNTech
Someone with a lot of money to spend has taken a bearish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on... 
Via Benzinga
BNTX Stock Alert: The Omicron Vaccine News That Has BioNTech Shooting Higher Today
BioNTech (BNTX) stock is rising higher on news it and Pfizer (PFE) can test a new Covid-19 vaccine for Omicron in adults. 
Via InvestorPlace
Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have started a clinical trial to test a new version of their vaccine specifically designed to target... 
Via Benzinga
The U.S. Stock Market Continues To Be In A Sell-Off
Yesterday, major US stock indices showed a sharp decline throughout the trading day, but at the end of the trading session recovered their positions sharply and closed in the green territory. 
Via Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,... 
Via Benzinga
Markets Fears
Today markets dropped precipitously over fear of a Ukrainian invasion and higher interest rates and inflation. 
Via Talk Markets
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or ... 
Via Benzinga
A Bearish Sign Appears On BioNTech's Chart
If history is any guide, there may be trouble ahead for shares of BioNTech (NASDAQ:BNTX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying... 
Via Benzinga
Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg
According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine... 
Via Benzinga
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
Key Takeaways Everest has signed a global licensing deal for an anti-viral Covid treatment being developed by Singapore’s Experimental Drug Development Centre Similar oral... 
Via Benzinga
Pfizer Trends Sideways, But A Looming Catalyst Could Arrive Next Month
This age group will likely require a three-dose primary series. 
Via Investor's Business Daily
Sputnik V Associated With Higher Antibody Levels Against Omicron Than Pfizer, Study Shows: Reuters
According to a small preliminary laboratory study, omicron-neutralizing antibodies in people vaccinated with Russia's Sputnik V vaccine did not decline as much as of... 
Via Benzinga
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
62 63 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.